TD Cowen Maintains Buy on Krystal Biotech, Raises Price Target to $403

Benzinga Newsdesk www.benzinga.com Positive 89.0%

Neg 0% Neu 0% Pos 89%

TD Cowen analyst Ritu Baral maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and raises the price target from $306 to $403.